Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metformin, a common type II diabetes drug, shows potential anti-cancer properties.
• The precise mechanisms of metformin's anti-cancer effects are not fully understood.

Purpose of the Study:

• To investigate the inhibitory effects of metformin on osteosarcoma.
• To elucidate the molecular mechanisms underlying metformin's action in osteosarcoma.

Main Methods:

• Cell cycle analysis (G2/M phase arrest) in osteosarcoma cell lines (U2OS, 143B).
• Assessment of programmed cell death (apoptosis and autophagy) induction.
• Evaluation of reactive oxygen species (ROS) and JNK/c-Jun signaling pathway involvement using NAC and SP600125.
• In vivo studies to assess metformin's efficacy in inhibiting osteosarcoma growth.

Main Results:

• Metformin treatment caused G2/M phase cell cycle arrest in osteosarcoma cells.
• Metformin induced apoptosis and autophagy in osteosarcoma cell lines.
• The effects of metformin were partially blocked by ROS scavenger NAC and JNK inhibitor SP600125.
• Metformin activated the ROS-dependent JNK/c-Jun signaling pathway.
• Metformin demonstrated safe and effective inhibition of osteosarcoma growth in vivo.

Conclusions:

• Metformin induces cell cycle arrest and programmed cell death (apoptosis, autophagy) in human osteosarcoma.
• This action is mediated through a ROS-dependent JNK/c-Jun signaling cascade.
• Metformin presents a promising therapeutic agent for osteosarcoma with potential molecular targets identified.